Citations (5)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Marie Fournier, Chieh-I Chen, Andreas Kuznik, Clare Proudfoot, Usha G Mallya & Kaleb Michaud. (2019) Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient. ClinicoEconomics and Outcomes Research 11, pages 117-128.
Read now
Read now
Yoshiya Tanaka, Tsutomu Takeuchi, Masayoshi Harigai, Hisashi Yamanaka, Toshikazu Nakano, Koshiro Akagi, Yoshifumi Ukyo & Benjamin Hsu. (2019) Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T). Modern Rheumatology 29:2, pages 306-313.
Read now
Read now
Alfonso E Bello, Elizabeth L Perkins, Randy Jay & Petros Efthimiou. (2017) Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatology: Research and Reviews 9, pages 67-79.
Read now
Read now
Articles from other publishers (2)
Vijay Kumar, Ankita Leekha, Ankur Kaul, Anil Kumar Mishra & Anita Kamra Verma. (2020) Role of folate-conjugated glycol-chitosan nanoparticles in modulating the activated macrophages to ameliorate inflammatory arthritis: in vitro and in vivo activities. Drug Delivery and Translational Research 10:4, pages 1057-1075.
Crossref
Crossref
Alvin F. Wells, Janie Parrino, Erin K. Mangan, Anne Paccaly, Yong Lin, Christine Xu, Chunpeng Fan, Neil M. H. Graham, Hubert van Hoogstraten & Albert Torri. (2019) Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs. Rheumatology and Therapy 6:3, pages 339-352.
Crossref
Crossref